Comparative efficiency of pathogen treatment of acute respiratory viral infections
- Authors: Petlenko S.V.1, Osidak L.V.2, Smirnov V.S.1, Stukan’ N.I.1, Afanas’Eva O.I.2, Golovacheva E.G.2
-
Affiliations:
- Biomedical Research and Production Complex “Cytomed”
- Research Institute of Influenza
- Issue: Vol 61, No 6 (2016)
- Pages: 263-269
- Section: ORIGINAL RESEARCHES
- URL: https://journal-vniispk.ru/0507-4088/article/view/117896
- DOI: https://doi.org/10.18821/0507-4088-2016-61-6-263-269
- ID: 117896
Cite item
Full Text
Abstract
The article presents the results of clinical studies on the comparative effectiveness of different forms of the drug Cytovir-3 (syrup and powder for solution for oral administration) and Immunal l in the treatment of acute respiratory viral infections in children. It was found in a comparative randomized parallel-group study of 90 children aged two through six years that the drug Cytovir-3 (syrup and powder) became active faster than the comparison drug Immunal, providing normalization of body temperature, reduction of some manifestations of the general intoxication and respiratory syndrome, as well as elevated levels of serum immunoglobulin A. All drugs in the study had an equally normalizing effect on the content of peripheral blood leukocytes and erythrocyte sedimentation rates. The compared products were characterized by good tolerability, lack of side effects and high preventive efficacy against respiratory disease complications. Cytovir-3 drugs (syrup and powder for oral solution) and Immunal had similar ratios of clinical and laboratory safety, efficacy and tolerability. Both products can be used for the treatment of respiratory diseases in children aged two through six years.
About the authors
S. V. Petlenko
Biomedical Research and Production Complex “Cytomed”
Author for correspondence.
Email: petlenko@mail.ru
Russian Federation
L. V. Osidak
Research Institute of InfluenzaRussian Federation
V. S. Smirnov
Biomedical Research and Production Complex “Cytomed”Russian Federation
N. I. Stukan’
Biomedical Research and Production Complex “Cytomed”Russian Federation
O. I. Afanas’Eva
Research Institute of InfluenzaRussian Federation
E. G. Golovacheva
Research Institute of InfluenzaRussian Federation
References
- Зарубаев В.В., Смирнов В.С. Воздействие на клеточные мишени как средство борьбы с гриппозной инфекцией. Инфекция и иммунитет. 2014; 4(1): 15-26.
- Киселев О.И. Химиопрепараты и химиотерапия гриппа. СПб.: Росток; 2012.
- Monod A., Swale C., Tarus B., Tissot A., Delmas B., Ruigrok R.W. et al. Learning from structure-based drug design and new antivirals targeting the ribonucleoprotein complex for the treatment of influenza. Expert Opin. Drug. Discov. 2015; 10(4): 345-71.
- Маркина М.В. Общеклинические анализы крови, мочи, их показатели, референсные значения, изменение параметров при патологии. Новосибирск; 2006.
- Van der Vries E., Schutten M., Fraaij P., Boucher C., Osterhaus A. Influenza virus resistance to antiviral therapy. Adv. Pharmacol. 2013; 67: 217-46.
- Романцов М.Г., Горячева Л.Г., Коваленко А.Л. Противовирусные и иммунотропные препараты в детской практике. СПб.; 2008.
- Fedson D.S. Treating influenza with statins and other immunomodulatory agents. Antiviral Res. 2013; 99(3): 417-35.
- Смирнов В.С. Профилактика и лечение гриппа и острых респираторных вирусных инфекций. СПб.: ФАРМИндекс; 2012.
- Karsch-Völk M., Barrett B., Kiefer D., Bauer R., Ardjomand-Woelkart K., Linde K. Echinacea for preventing and treating the common cold. Cochrane Database Syst. Rev. 2014; (2): CD000530.
- Lindenmuth G.F., Lindenmuth E.B. The efficacy of echinacea compound herbal tea preparation on the severity and duration of upper respiratory and flu symptoms: a randomized, double-blind placebocontrolled study. J. Altern. Complement. Med. 2000; 6(4): 327-34.
- Смирнов В.С., Куликов С.В., Власов В.Ю. Фармацевтическая композиция для лечения вирусных заболеваний. Патент РФ № 2155254; 2001.
- Эберт Л.Я., Бухарин О.В., Брауде А.И. Профилактика инфекционных заболеваний лекарственными средствами. Челябинск; 1968.
- Смирнов В.С., ред. Клиническая фармакология тимогена. СПб.: ФАРМИндекс; 2004.
- Смирнов В.С., Селиванов А.А. Биорегуляторы в профилактике и лечении гриппа. СПб.: Наука; 1996.
- Bowie A.G., O’Neill L.A. Vitamin C inhibits NF-kB activation by TNF via the Activation of p38 mitogen-activated protein kinase. J. Immunol. 2000; 165: 7180-8.
- Шипицын К.С., Огарков П.И., Смирнов В.С., Жоголев С.Д., Жоголев К.Д. Профилактика острых респираторных вирусных инфекций и пневмоний в организованном коллективе. Эпидемиология и инфекционные болезни. 2010; (1): 57-61.
- Fashner J., Ericson K., Werner S. Treatment of the common cold in children and adults. Am. Fam. Physician. 2012; 86(2): 153-9.
- Schapowal A. Efficacy and safety of Echinaforce® in respiratory tract infections. Wien. Med. Wochenschr. 2013; 163(3-4): 102-5.
- Сборник методических рекомендаций по выделению вирусов, ИФ и ПЦР-диагностике гриппа и вводу данных сигнального надзора в системе on-line. СПб.: Медицинское информационное агентство; 2011.
- Галкина О.В., Грязева И.В., Самойлович В.Б. Количественное определение секреторного иммуноглобулина А в биологических жидкостях с помощью моноклональных антител. Медицинская иммунология. 2000; 2(2): 155.
- Loregian A., Mercorelli B., Nannetti G., Compagnin C., Palù G. Antiviral strategies against influenza virus: towards new therapeutic approaches. Cell Mol. Life Sci. 2014; 71(19): 3659-83.
- Giles J.T., Palat C.T.3rd., Chien S.H., Chang Z.G., Kennedy D.T. Evaluation of echinacea for treatment of the common cold. Pharmacotherapy. 2000; 20(6): 690-7.
- Woelkart K., Linde K., Bauer R. Echinacea for preventing and treating the common cold. Planta Med. 2008; 74(6): 633-7.
Supplementary files
